Pfizer (NYSE:PFE – Get Free Report) and Tilray Brands (NASDAQ:TLRY – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership and earnings.
Institutional and Insider Ownership
68.4% of Pfizer shares are held by institutional investors. Comparatively, 9.3% of Tilray Brands shares are held by institutional investors. 0.6% of Pfizer shares are held by company insiders. Comparatively, 1.6% of Tilray Brands shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Pfizer and Tilray Brands’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Pfizer | 6.34% | 19.88% | 8.52% |
| Tilray Brands | -16.91% | -10.39% | -7.38% |
Analyst Recommendations
This is a breakdown of recent ratings and price targets for Pfizer and Tilray Brands, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Pfizer | 2 | 14 | 6 | 0 | 2.18 |
| Tilray Brands | 2 | 2 | 3 | 1 | 2.38 |
Pfizer currently has a consensus target price of $30.32, indicating a potential upside of 10.59%. Tilray Brands has a consensus target price of $5.90, indicating a potential upside of 212.17%. Given Tilray Brands’ stronger consensus rating and higher possible upside, analysts clearly believe Tilray Brands is more favorable than Pfizer.
Risk and Volatility
Pfizer has a beta of 0.31, suggesting that its share price is 69% less volatile than the S&P 500. Comparatively, Tilray Brands has a beta of 2.04, suggesting that its share price is 104% more volatile than the S&P 500.
Earnings and Valuation
This table compares Pfizer and Tilray Brands”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Pfizer | $62.58 billion | 2.50 | $7.77 billion | $0.70 | 39.16 |
| Tilray Brands | $915.45 million | 0.31 | -$121.40 million | ($1.40) | -1.35 |
Pfizer has higher revenue and earnings than Tilray Brands. Tilray Brands is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.
Summary
Pfizer beats Tilray Brands on 9 of the 14 factors compared between the two stocks.
About Pfizer
Pfizer Inc. is a global biopharmaceutical company that researches, develops, manufactures and commercializes prescription medicines and vaccines. Its work spans areas including oncology, vaccines, internal medicine, inflammation and immunology, rare diseases, and infectious diseases. The company’s products include the Prevnar family of vaccines and medicines such as Eliquis, which it commercializes with Bristol Myers Squibb, and Paxlovid. Pfizer also developed the Comirnaty COVID-19 vaccine with BioNTech.
About Tilray Brands
Tilray Brands is a global cannabis and consumer packaged goods company. Its cannabis business produces and sells medical and adult-use products, including dried flower, oils, extracts and edibles, under brands such as Good Supply, Solei, Redecan and Broken Coast. The company serves customers in Canada, the United States and international markets. Its activities include medical cannabis distribution in countries where permitted, as well as cannabis and hemp-related products in North America, subject to local regulations.
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
